The gut-liver axis in fatty liver disease: role played by natural products

被引:4
|
作者
Ming, Zhu [1 ,2 ]
Ruishi, Xie [1 ,2 ]
Linyi, Xu [1 ,2 ]
Yonggang, Yang [3 ]
Haoming, Luo [1 ,2 ]
Xintian, Lan [1 ,2 ]
机构
[1] Changchun Univ Chinese Med, Changchun, Peoples R China
[2] Changchun Univ Chinese Med, Sch Pharm, Changchun, Peoples R China
[3] Baicheng Med Coll, Baicheng 137000, Peoples R China
基金
中国国家自然科学基金;
关键词
gut-liver axis; NAFLD; ALD; natural products; plant metabolites; MICROBIOTA; INJURY; MICE; MECHANISMS; DYSBIOSIS; CIRRHOSIS; BARRIER; PAEONOL; ACIDS;
D O I
10.3389/fphar.2024.1365294
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fatty liver disease, a condition characterized by fatty degeneration of the liver, mainly classified as non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD), has become a leading cause of cirrhosis, liver cancer and death. The gut-liver axis is the bidirectional relationship between the gut and its microbiota and its liver. The liver can communicate with the gut through the bile ducts, while the portal vein transports the products of the gut flora to the liver. The intestinal flora and its metabolites directly and indirectly regulate hepatic gene expression, leading to an imbalance in the gut-liver axis and thus contributing to the development of liver disease. Utilizing natural products for the prevention and treatment of various metabolic diseases is a prevalent practice, and it is anticipated to represent the forthcoming trend in the development of drugs for combating NAFLD/ALD. This paper discusses the mechanism of the enterohepatic axis in fatty liver, summarizes the important role of plant metabolites in natural products in fatty liver treatment by regulating the enterohepatic axis, and provides a theoretical basis for the subsequent development of new drugs and clinical research.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] The gut-liver axis in liver disease: Pathophysiological basis for therapy
    Albillos, Agustin
    de Gottardi, Andrea
    Rescigno, Maria
    JOURNAL OF HEPATOLOGY, 2020, 72 (03) : 558 - 577
  • [42] Rosa rugosa polysaccharide attenuates alcoholic liver disease in mice through the gut-liver axis
    Li, Hailong
    Xie, Ziyang
    Zhang, Yao
    Liu, Yue
    Niu, Aijing
    Liu, Yingying
    Zhang, Linbo
    Guan, Lili
    FOOD BIOSCIENCE, 2021, 44
  • [43] Prebiotics targeting gut-liver axis to treat non-alcoholic fatty liver disease
    Castelnuovo, Gabriele
    Perez-Diaz-Del-Campo, Nuria
    Guariglia, Marta
    Poggiolini, Irene
    Armandi, Angelo
    Rosso, Chiara
    Caviglia, Gian P.
    Bugianesi, Elisabetta
    MINERVA GASTROENTEROLOGY, 2024, 70 (04): : 446 - 453
  • [44] JiGuCao capsule formula alleviates metabolic fatty liver disease by regulating the gut-liver axis and lipid metabolism
    Qi, Wenying
    Cao, Xu
    Chen, Yue
    Chen, Hening
    Zhang, Ningyi
    Liu, Ruijia
    Wang, Wei
    Liu, Qiyao
    Zheng, Shihao
    Li, Size
    Li, Xiaoke
    Zao, Xiaobin
    Ye, Yong'an
    PHYTOMEDICINE, 2025, 140
  • [45] Targeting Gut-Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension
    Kalo, Eric
    Read, Scott
    Ahlenstiel, Golo
    LIVERS, 2021, 1 (03): : 147 - 179
  • [46] The liver X receptor: A master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease
    Ducheix, Simon
    Montagner, Alexandra
    Theodorou, Vassilia
    Ferrier, Laurent
    Guillou, Herve
    BIOCHEMICAL PHARMACOLOGY, 2013, 86 (01) : 96 - 105
  • [47] Hepatology Snapshot: Role of bile acids in the gut-liver axis
    Schneider, Kai Markus
    Albers, Stefanie
    Trautwein, Christian
    JOURNAL OF HEPATOLOGY, 2018, 68 (05) : 1083 - 1085
  • [48] Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
    Nair, Bhagyalakshmi
    Kamath, Adithya Jayaprakash
    Tergaonkar, Vinay
    Sethi, Gautam
    Nath, Lekshmi R.
    LIFE SCIENCES, 2024, 351
  • [49] Regulatory mechanisms of the probiotic-targeted gut-liver axis for the alleviation of alcohol-related liver disease: a review
    Yang, Feiyu
    Li, Xiangfei
    Sun, Jing
    Pang, Xinyi
    Sun, Quancai
    Lu, Yingjian
    CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION, 2025,
  • [50] The Gut-Liver Axis in Cholestatic Liver Diseases
    Blesl, Andreas
    Stadlbauer, Vanessa
    NUTRIENTS, 2021, 13 (03) : 1 - 32